REG - Indivior PLC - Indivior to Participate in Upcoming Conferences

IndiviorAnnouncement

25/05/2023 14:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230525:nRSY6604Aa&default-theme=true

RNS Number : 6604A  Indivior PLC  25 May 2023

 

 

Indivior To Participate In Upcoming Investor Conferences

 

Slough, UK, and Richmond, VA, May 25, 2023 - Indivior PLC (LSE: INDV) today
announced that it will participate in the following investor events:

 

·    Jefferies Healthcare Conference - New York City, June 7(th)

Mark Crossley, Chief Executive Officer (CEO) and Ryan Preblick, Chief
Financial Officer (CFO), will host 1x1/group meetings on Wednesday, June 7(th)
and host a presentation Wednesday June 7(th) at 3:00 p.m. US EST.  Investors
can contact their Jefferies representative to schedule a meeting.  The
presentation will be available at www.indivior.com (http://www.indivior.com)
and can also be viewed using the following webcast link:
https://wsw.com/webcast/jeff281/indv.l/2074930
(https://wsw.com/webcast/jeff281/indv.l/2074930)

 

·    Stifel European Healthcare Summit - Bordeaux, France, June 29(th) and
30(th)

Mark Crossley, CEO, will participate in the Stifel European Healthcare
Conference in Bordeaux, France.  Mr. Crossley will host 1x1/group meetings on
Thursday, June 29(th) and Friday, June 30(th).  Investors can contact their
Stifel representative to schedule a meeting.

About Indivior

Indivior is a global pharmaceutical company working to help change patients'
lives by developing medicines to

treat substance use disorders (SUD) and serious mental illnesses. Our vision
is that all patients around the world

will have access to evidence-based treatment for the chronic conditions and
co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from
a global human crisis to a recognized and treated chronic disease. Building on
its global portfolio of OUD treatments, Indivior has a pipeline of product
candidates designed to both expand on its heritage in this category and
potentially address other chronic conditions and co-occurring disorders of
SUD, including alcohol use disorder and cannabis use disorder. Headquartered
in the United States in Richmond, VA, Indivior employs more than 1,000
individuals globally and its portfolio of products is available in 39
countries worldwide. Visit www.indivior.com to learn more. Connect with
Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

 

Contact:

Jason Thompson

Vice President, Investor Relations

Tel: 804-402-7123 or jason.thompson@indivior.com
(mailto:jason.thompson@indivior.com)

 

Tim Owens

Director, Investor Relations

Tel: 804-263-3978 or timothy.owens@indivior.com
(mailto:timothy.owens@indivior.com)

 

###

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEANSSAENDEEA